Identification of small molecule inhibitors of Neutral Sphingomyelinase 2 (nSMase2) as a new therapeutic approach for the treatment of neurodegenerative disorders

在此期间，NCGC一直致力于验证和表征先前在主要nSMase2筛查中发现的hit。

During this period, the NCGC has worked to validate and characterize hits previously identified in the primary nSMase2 screen. As a center, the NCGC has fostered and maintained over 110 active collaborations with both NIH and extramural investigators, facilitating drug discovery efforts across the entire spectrum of human disease. These efforts have led to dozens of high-throughput screens and a number of medicinal chemistry campaigns to further improve on screening hits, providing our collaborators and the general research community with publications and a variety of promising small molecule probes and leads. In addition, the NCGC has worked to advance a number of informatic initiatives to make better use of existing drug and disease target information and provide the general public with easily accessible resources, further catalyzing the development of new therapies for human disease.